PLASMA CELL MYELOMA

This study tested a personalized geriatric optimization plan (GO!) in 30 patients over 60 receiving a stem cell transplant for blood cancers or bone marrow failure. The plan included tailored changes to diet, sleep, activity, and medications. The goal was to see if these changes …

This study tested whether adding the drug isatuximab to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has come back or stopped responding to treatment. 302 adults who had already tried 1 to 3 prior therapies took part. The mai…

This study tested whether adding two drugs (ixazomib and dexamethasone) to the standard maintenance drug lenalidomide could better control multiple myeloma that remains after a stem cell transplant. 42 adults who had already started lenalidomide maintenance were randomly assigned…

This study looked at 77 people with multiple myeloma or non-Hodgkin lymphoma who had a stem cell transplant. Half got a growth factor (tbo-filgrastim) after transplant and half did not. The goal was to see if skipping the growth factor still allowed patients to leave the hospital…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by donor stem cells to help destroy c…

This study tested a drug called daratumumab in 49 patients with multiple myeloma who were eligible for a stem cell transplant. The goal was to see if adding daratumumab before and after transplant could clear more cancer cells from the bone marrow. Results focused on how many pat…

This study tested whether giving two drugs (ixazomib and lenalidomide) in an alternating schedule after a stem cell transplant could safely help keep multiple myeloma from coming back. Thirty patients who had already received a transplant took part. The main goal was to check for…

This early-stage study tested a new drug called SAR442085 in 37 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to find a safe dose and check for early signs that the drug can shrink or control the cancer. The study is…

This study looked at whether giving a multiple myeloma drug (daratumumab) at home instead of at the cancer center could make treatment easier for patients. Twenty adults with multiple myeloma who were already on a monthly daratumumab regimen received their injections at home. The…

This study tested whether a battery-powered drill makes bone marrow biopsies less painful and easier for patients compared to the standard manual needle. 100 people with plasma cell disorders took part. The goal was to see if the drill could improve comfort and still get good-qua…

This study involved 56 older adults (65+) with multiple myeloma to see if a comprehensive geriatric assessment—a series of questions and tests about physical and mental health—along with blood tests, could predict who would have more side effects from chemotherapy. The goal is to…